Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

Genzyme, a Sanofi Company6 enrolled

Overview

This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.

As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Lymphocytic Leukemia

Interventions

Alemtuzumab (MabCampath)DRUG

Intravenous therapy according to product information.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: In- and outpatients suffering from CLL, who are treated with Mab Campath, and are routinely monitored with PCR (Polymerase Chain Reaction) for CMV infection during MabCampath treatment and for at least 2 months following completion of treatment. Exclusion Criteria: In accordance with Summaries of Product Characteristics (SPC).

Locations (3)

Unnamed facility

Many Locations, Bosnia and Herzegovina

Unnamed facility

Many Locations, Israel

Unnamed facility

Many Locations, North Macedonia

Outcomes

Primary Outcomes

Efficacy related variables are patient's condition, physician's assessment of efficacy and tolerability, information whether application could be completed, clinical and laboratory findings. Safety Variables.

Time frame: After first cycle of treatment, e.g. 12 weeks, then after 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.